AIMイムノテック (AIM ImmunoTech)、新型コロナウイルス感染症の罹患後症状の治療薬としてAmpligen®を評価する第2相試験で最初の被験者を登録、投薬
10 juil. 2023 12h58 HE
|
AIM ImmunoTech Inc.
アンプリジェンの初期データは、新型コロナウイルス感染症の罹患後症状に対する有効な治療オプションとなる可能性を示す 登録完了は2023年第4四半期の予定 フロリダ州オカラ発, July 11, 2023 (GLOBE NEWSWIRE) -- AIMイムノテック(NYSE American: AIM) (以下「AIM」)...
AIM ImmunoTech 在评估 Ampligen® 治疗 COVID 后遗症的 2 期研究中招募首位受试者并完成给药
10 juil. 2023 12h58 HE
|
AIM ImmunoTech Inc.
Ampligen 的初步数据显示其有望成为治疗 COVID 后遗症的有效选择 预计招募将在 2023 年第四季度完成 佛罗里达州奥卡拉, July 11, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”)今天宣布已在该公司评估 Ampligen® 作为潜在治疗 COVID 后遗症的药物...
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
10 juil. 2023 08h05 HE
|
AIM ImmunoTech Inc.
Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 ...
AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series
05 juil. 2023 08h35 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech 宣布在《美国癌症研究杂志》上发表一项评估 Ampligen® 治疗胰腺癌的临床前研究取得的积极结果。
28 juin 2023 11h36 HE
|
AIM ImmunoTech Inc.
佛罗里达州奥卡拉, June 28, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)（以下简称“AIM”或“公司”）今日宣布发表临床前数据，数据表明 Ampligen 有可能直接作用于肿瘤细胞，抑制肿瘤细胞在肿瘤 TLR-3 水平足够的胰腺癌患者中的生长，这意味着有种潜在的生物标志物可识别出可能对...
AIM ImmunoTech 宣布获得荷兰主管机构和伦理委员会的批准，开始一项评估 Ampligen® (rintatolimod) 与 AstraZeneca 的 Imfinzi (durvalumab) 联合治疗胰腺癌的 1b/2 期研究
27 juin 2023 12h49 HE
|
AIM ImmunoTech Inc.
Ampligen 已显示出检查点抑制剂的治疗协同作用，具有提高存活率与疗效的潜力。 患者入组预计于 2023 年底前开始 佛罗里达州奥卡拉, June 28, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)（以下简称“AIM”或“公司”）今日宣布已获得荷兰的所需批准，Erasmus...
AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research
27 juin 2023 11h16 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., June 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its TLR-3...
AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
27 juin 2023 08h45 HE
|
AIM ImmunoTech Inc.
Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy Patient enrollment expected to commence before the end of 2023 OCALA, Fla.,...
AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
14 juin 2023 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments
12 juin 2023 08h45 HE
|
AIM ImmunoTech Inc.
Company’s priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site now open at University of Nebraska for Phase 2 study of Ampligen® for the...